The vector of anti-LMP2 T cell receptor (TCR) is constructed for the engineering of T cell to target EBV LMP2. The T cells are genetically modified through transduction with a lentiviral vector expressing LMP2-specific T cell receptor. And the vector product was designed for the treatment of Hodgkin's disease.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
|TCR-C109Z||Human anti-LMP2 T cell receptor (NB20), pCDTCR1|
|TCR-C110Z||Human anti-LMP2 T cell receptor (PL5.05), pCDTCR1|
|VP-TCR-C212||Lenti-LMP2 T cell receptor (Codon optimized and cysteine modified) Viral Particle|
|VP-TCR-C210||Lenti-LMP2 T cell receptor (PL5.04) Viral Particle|
|TCR-C112Z||Murinized anti-LMP2 T cell receptor, pCDTCR1|
|VP-TCR-C214||Lenti-EBV T cell receptor Viral Particle|
|VP-TCR-C215||Lenti-EBV (TYPVLEEMF) T cell receptor Viral Particle|
|TCR-L015||Human anti-LMP2 (FLRGRAYGL) T Cell Receptor, pMP71|
|TCR-C108Z||Human anti-LMP2 T cell receptor (8), pCDTCR1|
|VP-TCR-C216||Lenti-LMP2 T cell receptor Viral Particle|
Copyright © 2007 - 2018 Creative Biolabs. All Rights Reserved